Four months ago, the U.S. became one of 100 countries supporting the proposal presented a year ago to the World Trade Organization (WTO) by India and South Africa that intellectual property protection for COVID-19 vaccines be...more
10/22/2021
/ Coronavirus/COVID-19 ,
Infectious Diseases ,
Intellectual Property Protection ,
Manufacturers ,
Patent Ownership ,
Patient Access ,
Pharmaceutical Patents ,
Public Health Emergency ,
Social Equity Programs ,
TRIPS Agreement ,
Vaccinations ,
WTO
Last week we outlined our suggestions as to what an IPR petitioner should assert in an IPR action to avoid triggering the "could have raised" estoppel in a later filed district court action. But what if the party involved in...more
35 USC ยง315(e)(2) prohibits a petitioner (or real party in interest or privy of the petitioner) in an Inter Partes Review (IPR) of a patent claim from asserting in district court litigation that "the claim is invalid on any...more
Scenario: You are a chemical manufacturer and have created a chemical formulation that you intend to keep secret, to keep others from copying your product. The new formulation is hazardous and therefore must be handled with...more
On April 28, 2014 the U.S. Food and Drug Administration (FDA) published a final rule (the Rule), prohibiting statements on food product labels and dietary supplement labels that claim products are "high in," "rich in," or an...more